Cargando…
Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
Immunotherapy, especially based on chimeric antigen receptor (CAR) T cells, has achieved prominent success in the treatment of hematological malignancies. However, approximately 30-50% of patients will have disease relapse following remission after receiving CD19-targeting CAR-T cells, with failure...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603553/ https://www.ncbi.nlm.nih.gov/pubmed/33150182 http://dx.doi.org/10.1155/2020/8765028 |